Theriva Biologics, Inc.
TOVX
$0.32
-$0.02-5.60%
AMEX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 7.46% | 1.88% | -32.73% | -30.34% | -39.81% |
| Total Depreciation and Amortization | -21.17% | -27.52% | -23.65% | -12.68% | 1.48% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 27.59% | 59.37% | 1,814.26% | 360.34% | 354.06% |
| Change in Net Operating Assets | -521.21% | -218.21% | -134.30% | -87.43% | -68.56% |
| Cash from Operations | 1.58% | 1.64% | -1.37% | 7.97% | 10.84% |
| Capital Expenditure | -3,400.00% | 38.60% | 91.40% | 99.48% | 99.50% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -3,400.00% | 38.60% | 91.40% | 99.48% | 99.50% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -4.48% | -2.99% | 0.00% | -515.00% | 10.67% |
| Issuance of Common Stock | 214.02% | 24.24% | 447.40% | 150.70% | 150.70% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 188.15% | 218.37% | 213.69% | -- |
| Cash from Financing | 231.02% | 141.62% | 4,192.11% | 1,160.00% | 779.36% |
| Foreign Exchange rate Adjustments | 30.30% | -349.25% | -212.82% | 97.22% | -300.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 112.07% | 39.38% | 74.37% | 53.72% | 37.79% |